Description of the Invention
The company is dedicated in cryopreserving people’s own cells for future personalized regenerative therapeutics and genomic analysis to provide medically relevant foresight into patients’ current and future health. Cells are becoming the most valuable currency in therapeutics fueling advancements in tissue engineering, 3D organ printing, genetic engineering, and stem cell therapy. As we age, our cells degenerate exponentially and become poor therapeutic resources precisely when we will need them most. Fortunately, cells collected before the onset of disease and advanced age can be successfully cryopreserved, later to be grown and converted into therapeutic cells. Acorn Biolabs’ technology enables the non-invasive collection and mail-in transportation of therapeutically-capable cells harvested by clients directly from their own homes.
The core IP lies in its cell transportation and cryopreservation technologies. Plucked hair-follicular cells will travel in Acorn’s proprietary transportation media which we’ve demonstrated maximizes cellular health, stem cell differentiation, and enables viable cell transport. Viability testing protocols that assess the overall health and readiness of client-submitted cells before cryopreservation have been optimized to work hand-in-hand with Acorn’s cryopreservation protocols and proprietary cryo-media. Three years of research has gone into creating and optimizing these transportation and cryopreservation medias. They’ll have opened up the possibility of delivering cell-preservation through the mail without a health professional. The cell collection kit itself has been designed using a beautiful high-density, closed-cell EVA foam, optimized to protect cells from physical and thermal shock during transit.
All other companies in the cell-preservation space require invasive procedures and the presence of a health professional if not an entire surgical team. These companies have partnered with clinics to deliver their services, clients are forced to travel to a limited number of locations and undergo painful procedures, limiting their ability to scale. Costs to the client vary from more than double to 8-fold higher than Acorn’s. Acorn is leveraging recent advents in iPSC technology – the ability to convert any cell type into an embryonic-like stem cell – to eliminate the need to collect cells invasively. Combined with an at-home cell collection service, Acorn is poised to disrupt the personal cell preservation and genetics industries.